(Q39622232)

English

Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).

scientific article published on May 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

0 references

medical oncology

1 reference

based on heuristic

inferred from title

object named as

José Ramírez

8

0 references

object named as

Pilar Garrido

1

0 references

Enriqueta Felip

object named as

Enriqueta Felip

4

0 references

author name string

Javier de Castro

2

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Ángel Concha

3

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Dolores Isla

5

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Fernando López-Ríos

6

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Luis Paz-Ares

7

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Julián Sanz

9

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

José Javier Gómez

10

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Clinical and Translational Oncology

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

338-349

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

New driver mutations in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

Screening for epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

SEOM clinical guidelines for the treatment of non-small-cell lung cancer: an updated edition.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

The anaplastic lymphoma kinase in the pathogenesis of cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

Oncogene addiction

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

The biology and treatment of EML4-ALK non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

Somatic mutations affect key pathways in lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

Novel therapeutic inhibitors of the c-Met signaling pathway in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

The role of HER2/neu expression and trastuzumab in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

PIK3CA mutation and amplification in human lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0806-2

21 January 2018

PIK3CA mutation status in Japanese lung cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/22551539

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method

1 reference

https://pubmed.ncbi.nlm.nih.gov/22551539

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recommendations for mutational analysis of EGFR in lung carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22551539

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12094-012-0806-2

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39622232&oldid=2203033622"